231 related articles for article (PubMed ID: 32250264)
1. Vitiligo-like lesions developing upon immune checkpoint inhibition in advanced melanoma.
Grän F; Emmerich K; Mohme S; Goebeler M; Gesierich A
Eur J Dermatol; 2020 Feb; 30(1):72-73. PubMed ID: 32250264
[No Abstract] [Full Text] [Related]
2. [Vitiligo under checkpoint inhibitors].
Amini-Adle M; Dalle S
Ann Dermatol Venereol; 2018 Oct; 145(10):633-635. PubMed ID: 29866472
[No Abstract] [Full Text] [Related]
3. Vitiligo under anti-programmed cell death-1 therapy is associated with increased survival in melanoma patients.
Nardin C; Jeand'heur A; Bouiller K; Valnet-Rabier MB; Dresco F; Castagna J; Mareschal A; Carlet C; Nerich V; Limat S; Puzenat E; Aubin F
J Am Acad Dermatol; 2020 Mar; 82(3):770-772. PubMed ID: 31734192
[No Abstract] [Full Text] [Related]
4. Sarcoid-like reaction and vitiligo occurring after nivolumab therapy in a patient with metastatic melanoma.
Fukuchi K; Hikawa M; Sano Y; Kasuya A; Aoshima M; Tatsuno K; Nakamura Y; Kosugi I; Tokura Y
J Dermatol; 2019 Oct; 46(10):e359-e360. PubMed ID: 30985014
[No Abstract] [Full Text] [Related]
5. The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies.
Wu CE; Yang CK; Peng MT; Huang PW; Chang CF; Yeh KY; Chen CB; Wang CL; Hsu CW; Chen IW; Lin CT; Ueng SH; Lin G; Lin YF; Cheng CY; Chang JW
BMC Cancer; 2020 Oct; 20(1):1018. PubMed ID: 33087090
[TBL] [Abstract][Full Text] [Related]
6. Correlation between cutaneous adverse events and prognosis in patients with melanoma treated with nivolumab: A single institutional retrospective study.
Nakano E; Takahashi A; Namikawa K; Muto Y; Jinnai S; Kage Y; Mizuta H; Tsutsumida A; Yamazaki N
J Dermatol; 2020 Jun; 47(6):622-628. PubMed ID: 32162349
[TBL] [Abstract][Full Text] [Related]
7. Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: A multi-institutional retrospective study.
Matsuya T; Nakamura Y; Matsushita S; Tanaka R; Teramoto Y; Asami Y; Uehara J; Aoki M; Yamamura K; Nakamura Y; Fujisawa Y; Livingstone E; Zimmer L; Schadendorf D; Kagamu H; Fujimoto M; Honma M; Ishida-Yamamoto A; Araki R; Yamamoto A
J Dermatol; 2020 Jun; 47(6):629-635. PubMed ID: 32275100
[TBL] [Abstract][Full Text] [Related]
8. An update on the safety of nivolumab for the treatment of advanced melanoma.
Czarnecka AM; Rutkowski P
Expert Opin Drug Saf; 2020 Apr; 19(4):409-421. PubMed ID: 32293935
[No Abstract] [Full Text] [Related]
9. Vogt-Koyanagi-Harada-like syndrome induced by immune checkpoint inhibitors in a patient with melanoma.
Yoshida S; Shiraishi K; Mito T; Sayama K
Clin Exp Dermatol; 2020 Oct; 45(7):908-911. PubMed ID: 32394515
[No Abstract] [Full Text] [Related]
10. Single or dual immune checkpoint inhibitor as adjuvant therapy in advanced melanoma.
Fukumoto T; Horita N
Eur J Cancer; 2021 Apr; 147():140-141. PubMed ID: 33662688
[No Abstract] [Full Text] [Related]
11. Case of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab in a patient with advanced malignant melanoma.
Wada N; Uchi H; Furue M
J Dermatol; 2017 Aug; 44(8):e196-e197. PubMed ID: 28391613
[No Abstract] [Full Text] [Related]
12. Genital lichen sclerosus after nivolumab.
Miraglia E; Soda G; Giustini S
Dermatol Online J; 2020 Nov; 26(11):. PubMed ID: 33342187
[No Abstract] [Full Text] [Related]
13. Immune checkpoint inhibitors and pre-existing antinuclear antibodies: the rheumatologist point of view.
Ceccarelli F; Botticelli A; Natalucci F; Olivieri G; Cirillo A; Alessandri C; Marchetti P; Conti F
Clin Transl Oncol; 2021 Sep; 23(9):1961-1962. PubMed ID: 33728870
[No Abstract] [Full Text] [Related]
14. Nivolumab-induced multiple morphea associated with eosinophilic fasciitis.
Lacombe M; Bedane C; Delaumenie S; Bernard P
Eur J Dermatol; 2021 Dec; 31(6):844-846. PubMed ID: 34911674
[No Abstract] [Full Text] [Related]
15. Acute renal transplant rejection following nivolumab therapy for metastatic melanoma.
Tan B; Baxter M; Casasola R
BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33558380
[TBL] [Abstract][Full Text] [Related]
16. Vitiligo induced by immune checkpoint inhibitors in melanoma patients: an expert opinion.
Lommerts JE; Bekkenk MW; Luiten RM
Expert Opin Drug Saf; 2021 Aug; 20(8):883-888. PubMed ID: 33896329
[No Abstract] [Full Text] [Related]
17. Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma.
Gambichler T; Seifert C; Lehmann M; Lukas C; Scheel C; Susok L
Immunotherapy; 2020 May; 12(7):439-444. PubMed ID: 32308086
[No Abstract] [Full Text] [Related]
18. Immune checkpoint inhibitor-induced granulomatosis with polyangiitis.
Hung W; Cusnir I; Habib S; Smylie M; Solez K; Yacyshyn E
Rheumatology (Oxford); 2021 Jun; 60(6):e190-e191. PubMed ID: 33367837
[No Abstract] [Full Text] [Related]
19. A case of Schönlein-Henoch purpura induced by immune checkpoint inhibitor in a patient with metastatic melanoma.
Belkaid S; Berger M; Nouvier M; Picard C; Dalle S
Eur J Cancer; 2020 Nov; 139():169-172. PubMed ID: 32992155
[No Abstract] [Full Text] [Related]
20. Development of endocrine immune-related adverse events and improved survival in advanced melanoma patients treated with nivolumab monotherapy.
Maeda T; Yoshino K; Nagai K; Oaku S; Kato M; Hiura A; Hata H
Eur J Cancer; 2019 Jul; 115():13-16. PubMed ID: 31082687
[No Abstract] [Full Text] [Related]
[Next] [New Search]